Onabotulinumtoxin A ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
226	Interstitial cystitis with Hunners ulcer	2

51. Scleroderma

---

Clinical trials : 523 /  Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02165111 (ClinicalTrials.gov)	January 2015	11/6/2014	Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome	A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome	Scleroderma;Raynaud's Syndrome	Drug: Onabotulinumtoxin A;Drug: sterile saline solution	Johns Hopkins University	Allergan	Completed	18 Years	N/A	All	40	Phase 3	United States

226. Interstitial cystitis with Hunners ulcer

---

Clinical trials : 143 /  Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04401176 (ClinicalTrials.gov)	September 15, 2020	19/5/2020	Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A	Walter Reed National Military Medical Center	NULL	Recruiting	18 Years	N/A	Female	58	Phase 2	United States
2	NCT02297100 (ClinicalTrials.gov)	December 2014	30/9/2014	Intravesicular Onabotulinumtoxin A in Interstitial Cystitis	The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4	Interstitial Cystitis	Drug: Onabotulinumtoxin A;Procedure: injections upper aspect of trigone of urinary bladder;Procedure: injections on posterior bladder wall excluding the trigone	Wake Forest University Health Sciences	Allergan	Completed	18 Years	80 Years	Female	27	Phase 4	United States